



CDDF MULTI-STAKEHOLDER WORKSHOP

Access to Innovative Oncology Drugs in Europe

Madrid, Spain
7–8 September 2017

PROGRAMME



PROGRAMME

Day 1 Thursday 7 September 2017

- 13:30 **Introduction**
Lothar Bergmann (Frankfurt University Hospital, Germany)

SESSION 1: THE CHALLENGES



Chairs: Jorge Camarero & Heinz Zwierzina

- 13:40 **Keynote Lecture - Impact of Drug Access on Survival**
Lothar Bergmann (Frankfurt University Hospital, Germany)
- 14:00 **How to Involve Patients in HTA**
Matteo Scarabelli (EURORDIS, France)
- 14:20 **A Clinician's Point of View on How to Provide Best Therapy to their Cancer Patients**
Steen Werner Hansen (Herlev Hospital, Denmark)
- 14:40 **The Cancer Challenge – a Multi-Faceted Challenge**
Alexander Roediger (Chair EFPIA Oncology Steering Group, MSD, Switzerland)
- 15:00  **Roundtable discussion**
- 15:30  **Coffee break**

SESSION 2: CURRENT LANDSCAPE

Chairs: Lothar Bergmann & Ivana Cattaneo

- 16:00 **Differences of HTA in Europe**
Iñaki Imaz-Iglesia (EUnetHTA, Instituto de Salud Carlos III, Spain)
- 16:20 **Implications of Value-Based Pricing**
Afschin Gandjour (Frankfurt School of Finance & Management, Germany)
- 16:40 **Access to new drugs for metastatic melanoma in Europe and the role of ESMO Magnitude of Benefit Scale**
Lidija Kandolf Sekulovic (Military Medical Academy University of Belgrade, Serbia)
- 17:00 **Regulation / HTA – How to Define Common Grounds?**
Elisa Sulleiro (AEMPS, Spain)

- 17:20 **Pricing and Reimbursement Decisions in Germany**
Florian Jantschak (Federal Joint Committee - G-BA, Germany)
- 17:40 **Report on Drug Reimbursement**
Dr Marko Kavcic (Hospital of Ljubljana, Slovenia)
Jelena Roganović (Clinical Hospital Centre Rijeka, Croatia)
- 18:10  **Roundtable discussion**
- 18:40 End of the day
- 19:30  Networking Dinner

Day 2 Friday 8 September 2017


SESSION 3 : THE WAY AHEAD

Chairs: *Iñaki Imaz-Iglesia & Steen Werner Hansen*

- 09:00 **How to Create an Overall Win Situation?**
Ivana Cattaneo (Vice-Chair EFPIA Oncology Steering Group / Public Affairs Director, Novartis, Italy)
- 09:20 **How to Meet the Challenges of Affordability of Novel Anti-Cancer Drugs?**
Eveline Scheres (Dutch Cancer Foundation, The Netherlands)
- 09:40 **Industry Perspective**
Todd Riehl (Genentech, USA)
- 10:00 **Approaches for Payer's Decision**
Marc Van De Castele (RIZIV/INAMI, Belgium)
- 10:20  **Roundtable discussion**
- 10:50  Coffee break

SESSION 4 : TIME FOR A EUROPEAN HTA EVALUATION?

Chairs: *Lothar Bergmann & Francesco De Lorenzo*

- 11:20 **EU Initiatives on HTA**
Davide Integlia (Innovation Area I-Com, Institute for competitiveness, Italy)
- 11:40 **The EUnetHTA Experience – Lessons Learned for a New EU HTA Cooperation**
César Hernandez (AEMPS, Spain)
- 12:00 **What Cancer Patients Need From a European HTA**
Dan Cimpoeru (FABC, Romania)
- 12:20 **Cancer patients' role in HTA**
Deborah Maskens (International Kidney Cancer Coalition, Canada)
- 12:40  **Roundtable discussion**

SESSION 5 : WRAP-UP SESSION

- 13:10 **What can be done in the future?**
Next steps and objectives
- 13:40 End of the workshop

Event Outline

The goal of this workshop is to facilitate a collaborative discussion between regulatory bodies, HTA organizations, healthcare providers, academics, patients and industry on the challenges of equal access to oncology drugs within and between European countries.

Meeting Co-chairs

- Lothar Bergmann (Frankfurt University Hospital, Germany)
- Jorge Camarero (AEMPS, Spain)
- Francesco De Lorenzo (ECPC, Italy)

Meeting Venue

Tryp Atocha Hotel
Calle de Atocha, 83, Madrid 28012, Spain
Tel: (34) 91 3300500 Fax: (34) 91 4201560
E-mail: tryp.atocha@melia.com

Meeting Secretariat

The Cancer Drug Development Forum (CDDF) office
Avenue E. Mounier 83
1200 Brussels, Belgium
Phone: +32 (0)2 775 02 15
Email: cddf@ecco-org.eu



